报告人：黄力夫教授 （Prof. Leaf HUANG）
              北卡罗来纳大学教堂山分校Eshelman药学院制药工程与分子药剂学系的Fred Eshelman 杰出教授

报告题目：Overcoming the Suppressive Immune Microenvironment with Nanoparticles

报告时间：2018年04月27日下午3:30

报告地点：南开大学蒙民伟楼 201

报告人简介：
Professor Leaf Huang is the Fred Eshelman Distinguished Professor, Division of Pharmacoengineering and Molecular Pharmaceutics in the Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. Dr. Huang’s research focuses on non-viral gene therapy and targeted drug delivery of cancer. He has pioneered the liposome non-viral vector and has designed and manufactured the cationic lipid vector for the first non-viral clinical trial in 1992. He has authored or co-authored more than 500 papers with an H-index of 115. He is also the inventor or co-inventor of 21 US and foreign patents. Dr. Huang has also co-founded 6 biotech start-ups in the past.

报告摘要：
Many human solid tumors are immune suppressive leading to a poor response to immune therapy such as the checkpoint inhibitors. They have discovered that tumor associated fibroblasts, like tumor cells, over-express the sigma receptor which can be targeted with aminoethylanisamide as a ligand. Nanoparticles modified with AEAA are taken up by these cells with high efficiency. With additional designs for endosome escape and nuclear entry, plasmid DNA can be readily delivered to the tumor and be expressed locally and transiently. They have also designed fusion proteins that contain a high affinity binding domain, i.e. traps, for several chemo/cytokines and receptors. Nanoparticle delivery of the trap plasmid DNA to the tumor in several different orthotopic tumor models significantly remodeled the immune microenvironment. Trap therapy alone, or together with a checkpoint inhibitor, resulted in prolonged tumor growth inhibition and progression free survival of the host. Data will be presented for pancreatic, breast, colorectal cancers and melanoma.